15488results about "Urinary disorder" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

A nitrogen-containing fused ring compound as a GLP-1 receptor agonist, and a preparation method therefor and the use thereof. Specifically, provided are a compound as represented by formula (I), and the use thereof in the preparation of a drug for treating or preventing diseases mediated by GLP-1.

The invention discloses a nitrogen-containing bridged ring compound serving as a GLP-1 receptor agonist as well as a preparation method and application of the nitrogen-containing bridged ring compound. Specifically, the invention discloses a compound as shown in a formula (I), and application of the compound in preparation of drugs for treating or preventing GLP-1 mediated diseases. # imgabs0 #

The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

Provided are diaminocyclopentyl substituted heteroaryl derivatives, the use thereof and a preparation method therefor. In particular, the present disclosure relates to compounds represented by formula (I)each substituent of which is defined in the description, and a preparation method therefor. The compounds can be used as PCSK9 inhibitors to prevent and / or treat PCSK9-mediated diseases and disorders.

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT / L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention relates to a furan ring-containing compound as well as a pharmaceutical composition and application thereof. Specifically disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect (inhibiting effect) on the activity of a Nav1.8 channel; and (3) the compound has good selectivity to other subtypes of Nav and is high in safety. # imgabs0 #

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The preparation method comprises the following steps: mixing a tannic acid solution and a tetravalent cerium salt solution, adjusting the pH value to 9-11, and reacting to obtain the cerium tannate nano-enzyme, the molar ratio of the tannic acid to the tetravalent cerium salt is (1-4): 1; the hydration dynamic diameter of the cerium tannate nano-enzyme is 20 to 80 nm. The TA-Ce nano-enzyme prepared by the preparation method disclosed by the invention is smaller in particle size, can keep stable and good dispersibility in a physiological environment, and has good biocompatibility, low hemolysis rate and small systemic toxicity; meanwhile, the compound has good kidney targeting property, can be effectively enriched into the injured kidney, eliminates various ROS (reactive oxygen species) and relieves oxidative stress by utilizing unique redox cycle between Ce < 3 + > and Ce < 4 + > states, and has a good effect in treating acute kidney injury induced by rhabdomyolysis and / or cis-platinum. The research lays a foundation for the metal polyphenol nano material in the treatment of acute kidney injury.

The invention discloses a nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of nano-enzymes. According to the preparation method, natural polyphenol, a cerium source and polyethylene glycol are mixed to prepare the novel polyphenol nano-enzyme, the preparation method is simple and easy to implement, the preparation cost is low, the prepared nano-enzyme has good biocompatibility, and a new way is provided for effective treatment of inflammatory diseases.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI / SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI / SNF (BAF) chromatin remodeling complex proteins are also provided.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A, R1, R2, R3, R4, R9, m, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

The invention discloses a CA9-targeted chimeric antigen receptor and application thereof, and belongs to the technical field of biological medicines. The CA9 targeting chimeric antigen receptor provided by the invention comprises a CD8 alpha leading signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane structural domain and a CD3 zeta intracellular costimulatory signal transduction structural domain. According to the invention, an anti-CA9 single-chain variable fragment is used as an antigen binding structural domain to construct a chimeric antigen receptor (CAR) molecule, the macrophage expressing the anti-CA9CAR can realize specific targeting and phagocytosis killing of CA9 positive kidney cancer cells, and the constructed lipid nanoparticle delivery system can effectively transfer a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the CA9 positive kidney cancer cells can be effectively targeted and killed. The constructed hydrogel-liposome combined drug delivery system has the performance of relieving toxic and side effects, controllable release and hemostasis.

The invention relates to the technical field of health care products, and discloses kidney function health wine based on traditional Chinese medicine fermentation and a preparation method of the kidney function health wine. 6-10 parts of cistanche deserticola; 9-30 parts of radix astragali and 6-12 parts of fructus lycii; the fermentation strain comprises lactobacillus acidophilus, lactobacillus plantarum, bifidobacterium longum subsp. Longum, saccharomyces cerevisiae and bacillus subtilis, and the fermentation strain comprises the following strains: lactobacillus acidophilus JYLC-374, lactobacillus plantarum JYLC-482, bifidobacterium longum subsp. Longum JYBB-163, saccharomyces cerevisiae JYSC-710 and bacillus subtilis JYBS-312. By adopting the technical scheme that a traditional Chinese medicine compound formula is combined with specific probiotic fermentation, the technical effects of enhancing the bioavailability of active ingredients and promoting kidney function regulation are achieved, and the dissolution rate and the biotransformation rate of herbal medicine active substances are improved.

A compound as an LPAR1 antagonist, a pharmaceutical composition thereof and a use thereof. A compound represented by formula (I), as well as a racemate, stereoisomer, tautomer, nitrogen oxide, or pharmaceutically acceptable salt thereof. The compound of the LPAR1 antagonist has a good inhibitory effect on LPAR1, has excellent pharmacokinetic properties, and has good druggability.

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

Disclosed are naphthyl compounds comprising either a ureido piperidine-1 -carboxamide or a ureido piperidine-1 -carboxylate moiety, compositions thereof, and methods of use thereof, for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport, such as phenylketonuria, hyperphenylalaninemia, diabetes and chronic kidney disease.

The invention discloses a nanometer antibody targeting FAP, a CAR-T cell and application of the nanometer antibody and the CAR-T cell. The invention provides nano-antibodies VHH1 and VHH2 capable of simultaneously recognizing human or mouse FAP. The nano-antibodies VHH1 and VHH2 are used as antigen binding regions to be constructed in a human or mouse CAR structure, and human or mouse FAP-CAR-T cells with a killing function can be prepared. Results of the mouse FAP-CAR-T cell or the human FAP-CAR-T cell provided by the invention show that the FAP-CAR-T cell has a good treatment effect on removal of FAP positive cells, and is a novel FAP-CAR-T cell which is expected to be applied to clinical solid tumor CAR-T therapy.

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

The present invention discloses a series of fluorine-substituted heterocyclic compounds, specifically, compounds represented by formula (XII) and pharmaceutically acceptable salts thereof. 【Chemical 1】 JPEG2025516367000403.jpg44170

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof, which have better BRD4 inhibition and degradation effects as a drug, and can be used for preparing drugs related to BRD4 inhibition and degradation. And preventing and / or treating related diseases. # imgabs0 #